Clinical-grade wearable market seen topping $7.48 billion by 2030

The Business Research Company says clinical-grade wearables used in pharma and biotech are moving from niche tools to core trial infrastructure. The market is projected to grow from $2.83 billion in 2025 to $3.43 billion in 2026, with remote monitoring, AI analytics and decentralized trials driving demand.

Why it matters: - Clinical-grade wearables are becoming more important in drug development because they capture continuous patient data during trials. - The technology supports remote patient monitoring, real-world evidence and safety tracking without requiring as many in-person visits. - Faster adoption could help pharma and biotech firms run more efficient trials and make treatment decisions sooner.

What happened: - The Business Research Company published its Clinical-Grade Wearable For Pharma And Biotech Global Market Report 2026 on July 18, 2026. - The report estimates the market will grow from $2.83 billion in 2025 to $3.43 billion in 2026. - The report projects the market will reach $7.48 billion by 2030. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to grow faster than other regions over the forecast period. - The report covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Clinical-grade wearables are medical devices with sensors designed to collect continuous physiological and biological data with clinical-level precision. - The devices are used to support clinical trials, safety monitoring and therapeutic evaluation in pharma and biotech. - The market's recent growth is linked to wider use of wearable medical devices in clinical trials. - Demand for real-world patient data is also expanding the market. - Decentralized clinical trials are another growth driver. - Biosensor improvements and broader digital health infrastructure are adding support. - The report points to AI integration for clinical data analysis as a major future driver. - Other expected growth factors include personalized drug development, remote patient monitoring in trials, stronger regulatory acceptance of real-world evidence and next-generation wearable sensor innovation. - The report highlights AI-powered clinical data analytics platforms, IoT-enabled biosignal monitoring, cloud-based real-world evidence platforms, precision medicine-focused biomarker trackers and smart medical device manufacturing as key trends. - One cited Vivalink survey from August 2023 found that 84% of current RPM users planned to increase usage in 2024. - The same survey found 45% of providers use RPM for acute monitoring such as hospital-at-home programs. - The survey also found 77% of providers expect RPM-based care to surpass traditional inpatient care within five years. - The report says chronic diseases such as heart disease, diabetes and hypertension are increasing demand for remote monitoring. - Clinical-grade wearables help providers monitor trends, spot early deterioration and adjust treatment without in-person visits. - The report also lists expanded capabilities in its 2026 market reports, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The forecast suggests pharma and biotech are shifting toward continuous, data-heavy trial models that depend on connected devices and software, not just traditional site-based research. - North America's lead likely reflects deeper digital health adoption and clinical research spending, while Asia-Pacific's faster growth points to rising trial activity and infrastructure buildout. - The emphasis on AI, cloud platforms and IoT shows the market is moving toward integrated data systems rather than stand-alone hardware.

What's next: - The market is expected to keep expanding as remote monitoring becomes more common in clinical research. - Regulatory acceptance of real-world evidence could further accelerate adoption. - Next-generation sensor technology and AI analytics are likely to shape competition through 2030. - The Business Research Company says its Global Market Model provides updated forecasts to support decision-making.